基石藥業-B(02616.HK)「泰吉華」被納入2023年國家醫保藥品目錄

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

基石藥業-B(02616.HK)「泰吉華」被納入2023年國家醫保藥品目錄

阿思達克 12-13 12:09

基石藥業-B(02616.HK)公佈，泰吉華(阿伐替尼片)被納入2023年國家醫保藥品目錄，醫保支付範圍爲限攜帶血小板衍生生長因數受體α(PDGFRA)外顯子18突變的不可切除性或轉移性胃腸道間質瘤成人患者。新版國家醫保目錄將於2024年1月1日起正式生效。

基石药业-B(02616.HK)

Relevant Stocks

基石药业-B(02616.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

基石藥業-B(02616.HK)「泰吉華」被納入2023年國家醫保藥品目錄

Services

About Us

Agreement Statement